Moderna hopes to market a combined COVID and flu booster in 2023 – POLITICO

Moderna hopes to market a combined booster vaccination for COVID-19, influenza and RSV – a common respiratory virus – as soon as the fall of 2023, CEO St├ęphane Bancel said Monday.

Bancel, speaking in a panel at the World Economic Forum, said the combination vaccine would enable people to get broad protection against diseases caused by respiratory viruses ahead of the contagious winter season without having to get more jabs.

“Our goal is to be able to have a single annual booster so we do not have compliance issues where people do not want to get two to three shots in the winter,” Bancel said. “The best case scenario would be Fall 2023.”

Bancel told investors last September, Moderna was working on a booster shot that would combine its mRNA vaccine against COVID-19, a vaccine that it is developing against influenza and possibly a dose to treat respiratory syncytial virus or RSV.

The COVID booster is currently in phase three trials, he told the panel debate, while the flu vaccine under development – which also uses mRNA technology – should go from phase two to three trials in the second quarter. Investors sold Moderna shares after an update in December showed that it generated antibody levels against all four strains of the flu virus in an early study that was not as robust in older people as an existing Sanofi flu shot.

Moderna plans to ship 2 to 3 billion doses of COVID-19 vaccines this year, Bancel confirmed, after 807 million in 2021. The company is currently consulting with health authorities on the composition of the COVID-19 vaccine doses to be used in the autumn.


Give a Comment